Pharma Stability: Insights, Guidelines, and Expertise
Pharmaceutical products must be stored and tested under defined conditions to evaluate their shelf life, degradation profile, and packaging robustness. Without qualified stability chambers, stability data may be deemed unreliable by regulatory bodies.
Click to read the full article.
Intermediate condition studies are often required when:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
A bridging study is a scientifically justified approach to extrapolate stability data from one batch, packaging, or formulation to another. It leverages prior data to avoid redundant long-term studies and facilitates faster regulatory approvals.
Click to read the full article.
According to ICH Q8(R2), CQAs are defined as “a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.”
Click to read the full article.
Accelerated studies provide predictive insights into how a drug product degrades under elevated conditions, helping estimate its shelf life before long-term real-time data matures. However, submission of this data requires strict adherence to regulatory protocols.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.